Vaccine and Infectious Diseases Institute, Fred Hutchinson Cancer Research Center, USA.
AIDS. 2011 Jan 14;25(2):153-8. doi: 10.1097/QAD.0b013e328342115c.
adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition.
we performed a nested case-control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups.
in MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8-1.5, P = 0.57) and 1.0 (95% confidence interval 0.4-2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer.
the presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection.
腺病毒是开发 HIV 疫苗最有前途的载体之一。基于腺病毒血清型 5 的默克三价 HIV 疫苗的 IIB 期研究结果引起了人们的关注，即对腺病毒血清型 5（Ad5）的血清学免疫可能与高危人群中 HIV 获得风险有关。我们研究了血清型腺病毒状态与 HIV 获得风险升高人群中 HIV 感染发生率之间的关系。
我们对 299 名 HIV 感染者和 590 名匹配的 HIV 未感染者进行了 Ad5 血清状态的嵌套病例对照研究，这些人参加了多中心艾滋病队列研究（MACS）和 HPTN 039，这是一项在美国、南美洲和非洲成年人中单纯疱疹病毒 2 抑制的研究。在每个队列中都确定了适当的 HIV 病例和对照，并比较了这两组的 Ad5 中和抗体滴度。
在 MACS 和 HPTN 039 中，Ad5 血清阳性与 Ad5 血清阴性个体的 HIV 感染发生率的相对风险分别为 1.1（95%置信区间 0.8-1.5，P=0.57）和 1.0（95%置信区间 0.4-2.3，P=0.99）。Ad5 中和抗体滴度与 HIV-1 获得率无显著差异。
在 HIV 感染风险升高的人群中，存在 Ad5 中和抗体与 HIV 获得风险无关。
